Analysis of Niacin and Niacinamide market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Niacin is an organic compound with the chemical formula C6H5NO2 and is a form of Vitamin B3. In humans, Niacin deficiency can cause pellagra. Hence, it is one of the most important nutrients for humans.
Niacinamide, also known as Nicotinamide or nicotinic acid amide, is interchangeably used with niacin in the realm of essential supplements. Naturally, these are found in meat, beans, fish, eggs, yeast, and green vegetables. Niacin and niacinamide may be produced in different forms including powder, granular, and liquid.
These chemicals are widely accepted for a number of end uses such as human nutrition, pharmaceuticals, animal nutrition, cosmeceuticals, and others. The global niacin and niacinamide market is expected to witness a CAGR of ~5% in terms of value over the forecast period (2019 to 2027).
Focus of established players towards exploring the application area of niacin and niacinamide and dedicated strategies have been found as trending factors in the global niacin and niacinamide market.
Furthermore, increasing healthcare expenditure, inclination of consumers towards healthy eating styles, increasing demand for niacin and niacinamide in cosmeceutical products, and benefits of niacin and niacinamide against number of diseases are factors pushing the global niacin and niacinamide market growth.
However, significant side effects associated with niacin are projected to impede the niacin and niacinamide market growth over the forecast period.
Niacin and niacinamide are proven to be advantageous against various diseases including Pellagra, Melanoma, etc. Taking into account severe disorders such as Schizophrenia, these chemicals have provided noticeable results, and researchers are emphasizing on the intake of niacin and niacinamide to fight against Schizophrenia.
Schizophrenia is characterized by the combination of perceptual changes such as hallucinations and thought disorders such as delusions. The primary cause of schizophrenia is biochemical imbalance.
Schizophrenic toxin is an oxidized derivative of an adrenaline - Adrenochrome. To reduce Adrenochrome production, researchers across the globe are emphasizing on consuming niacinamide (vitamin B3). Previously employed for treating pellagra, a disease that is indistinguishable from schizophrenia, niacinamide comprises of relevant biochemical properties.
Oxidized nicotinamide adenine dinucleotide (NAD) and reduced nicotinamide adenine dinucleotide + hydrogen (NADH) forms in a human body comprise of vitamin B3, a precursor of niacinamide. There is enough availability of NAD and NADH support reconversion of oxidized adrenaline to adrenaline.
The process continues to occur, and it provides sufficient niacinamide coenzymes. Therefore, provision of vitamin B3 supplements such as niacinamide to all schizophrenic patients, including acute as well as chronic patients, is essential in maintaining a healthy life.
The practice further holds potential to provide significant hope of a sustainable life among schizophrenic patients, thereby, necessitating adherence of clinicians to this safe and effective treatment. Such treatments will bring about a paradigm shift in niacin and niacinamide market.
The application of niacin and niacinamide for enhancing animal nutrition accounts for ~60% of the market in terms of volume in 2018. Niacin and niacinamide have proven to be beneficial in terms of reducing “Ketosis” in dairy cattle, which help in higher milk production. Several high, milk-producing cattle exhibit borderline ketosis in early lactation.
However, high production causes strain on the manifested energy metabolism in elevated blood ketone and reduced blood-glucose levels in these animals. Closely linked with improving energy metabolism, niacin and niacinamide (vitamin B3) represents several benefits for persistence production of milk in dairy cattle. Therapeutic doses are meant to increase milk production, along with alleviated blood changes.
According to several lactation trials, cows that are supplemented with niacin are consistently producing relatively more milk with higher fat percentages, albeit with a slight difference. Small doses of niacin supplements during or after peak lactation are expected to prevent physiological symptoms associated with ketosis in dairy cattle.
Other than providing various benefits against number of diseases and being a major drug for cholesterol therapy, niacin and its amide are no longer advised to be prescribed to patients.
Adverse side effects and risks related to the consumption of these chemicals are restricting the adoption of niacin and niacinamide. Niacin, which proved to be advantageous in reducing heart attacks and strokes, is seen to be less effective nowadays.
Research studies over the past decade have shown that the aging population who consumed doses of niacin and niacinamide have not shown any significant results in terms of reduced heart attacks and stroke rates. Niacin was used for proliferating High Density Lipoprotein (HDL) cholesterol levels to reduce cardiovascular diseases risks.
However, some recent clinical trials have portrayed that this level has nothing to do with cardiovascular outcomes and triglyceride levels. Also, there have been various concerns with respect to liver problems, development of diabetes, excess infections, and excess bleeding.
Hence, all these factors are collectively projected to restrict the global niacin and niacinamide market growth over the forecast period.
Majority of the patients, who are affected with end-stage renal disorder, are found to develop hyperphosphatemia. These patients are, therefore, bound to oral phosphate binders to support their life-long phosphate management, along with maintenance of dialysis and dietary restrictions.
A traditional antilipemic agent, niacin, is gaining traction among physicians for the treatment of hyperphosphatemia. Owing to illuminating efficacy, safety, and clinical synergistic benefits of niacin, researchers are focusing on repurposing the antilipemic agent to treat hyperphosphatemia in dialysis patients.
In the upcoming years, niacin is most likely to be a cost-effective alternative and patient-convenient add-on therapy for dialysis patients’ phosphorus management. Additionally, well-designed, comparative, long-term, and large-scale clinical trials are being carried out globally for repurposing niacin in hyperphosphatemia therapeutics.
Europe has been accounted to hold ~one fourth of the global niacin and niacinamide market revenue in 2018. Prime factors attributed to its prominence are increasing DCS incidences in dairy cattle, rising instance of childhood obesity, along with the presence of key market players and unhealthy food consumption patterns.
Major portion of the European youths are witnessed to consume chocolates and carbonated or sugary drinks excessively, which led to significant increase in their body weights. Large portion of the population in the region is subjected to higher risk of obesity. Unhealthy consumption patterns and physical inactivity among individuals are some of the primary reasons behind obesity and their overweight characteristics.
Hence, governments of major countries are taking efforts to push the adoption of high nutritional foods, which further drive the Europe niacin and niacinamide market growth. For reducing childhood obesity, sugar reduction programs, soft drinks industry levy, and stringent regulations on advertising junk food to children are some of the initiatives taken up by European governments.
Additionally, countries in European region are facing downer cow syndrome (DCS) in dairy cattle, which results in low milk production due to reduced electrolyte metabolism. Governments, along with private institutions, are consistently focusing on spreading the awareness about benefits of niacin among dairy producers.
Moreover, increasing healthcare expenditure, coupled with the presence of key players are factors that further strengthen the Europe niacin and niacinamide market. Some of the major players are Lonza Group AG, Koninklijke DSM N.V., BASF SE, Evonik Industries AG, and others.
Fact.MR has studied the niacin and niacinamide market with detailed segmentation on the basis of form, end use, and region.
How much is the global market for niacin and niacinamide market worth?
As a result, the market will nearly double to reach a valuation of us$ 1.6 bn by 2027
What are the segments covered in the niacin and niacinamide market?
Fact.mr has studied the niacin and niacinamide market with detailed segmentation on the basis of form, end use, and region.
TABLE. 1 Global Market Value (US$ Mn), 2013 to 2018
TABLE. 2 Global Market Value (US$ Mn), 2019 to 2027
TABLE. 3 Global Market Value (US$ Mn) and Y-o-Y, 2019 to 2027
TABLE. 4 Global Powder Segment Value (US$ Mn), By Region 2013 to 2018
TABLE. 5 Global Powder Segment Volume (Tons), By Region 2013 to 2018
TABLE. 6 Global Powder Segment Value (US$ Mn), By Region 2019 to 2027
TABLE. 7 Global Powder Segment Volume (Tons), By Region 2019 to 2027
TABLE. 8 Global Powder Segment Market Share, By Region 2013 to 2018
TABLE. 9 Global Powder Segment Market Share, By Region 2019 to 2027
TABLE. 10 Global Powder Segment Y-o-Y, By Region 2019 to 2027
TABLE. 11 Global Granular Segment Value (US$ Mn), By Region 2013 to 2018
TABLE. 12 Global Granular Segment Volume (Tons), By Region 2013 to 2018
TABLE. 13 Global Granular Segment Value (US$ Mn), By Region 2019 to 2027
TABLE. 14 Global Granular Segment Volume (Tons), By Region 2019 to 2027
TABLE. 15 Global Granular Segment Market Share, By Region 2013 to 2018
TABLE. 16 Global Granular Segment Market Share, By Region 2019 to 2027
TABLE. 17 Global Granular Segment Y-o-Y, By Region 2019 to 2027
TABLE. 18 Global Liquid Segment Value (US$ Mn), By Region 2013 to 2018
TABLE. 19 Global Liquid Segment Volume (Tons), By Region 2013 to 2018
TABLE. 20 Global Liquid Segment Value (US$ Mn), By Region 2019 to 2027
TABLE. 21 Global Liquid Segment Volume (Tons), By Region 2019 to 2027
TABLE. 22 Global Liquid Segment Market Share, By Region 2013 to 2018
TABLE. 23 Global Liquid Segment Market Share, By Region 2019 to 2027
TABLE. 24 Global Liquid Segment Y-o-Y, By Region 2019 to 2027
TABLE. 25 Global Human Nutrition Segment Value (US$ Mn), By Region 2013 to 2018
TABLE. 26 Global Human Nutrition Segment Volume (Tons), By Region 2013 to 2018
TABLE. 27 Global Human Nutrition Segment Value (US$ Mn), By Region 2019 to 2027
TABLE. 28 Global Human Nutrition Segment Volume (Tons), By Region 2019 to 2027
TABLE. 29 Global Human Nutrition Segment Market Share, By Region 2013 to 2018
TABLE. 30 Global Human Nutrition Segment Market Share, By Region 2019 to 2027
TABLE. 31 Global Human Nutrition Segment Y-o-Y, By Region 2019 to 2027
TABLE. 32 Global Pharmaceuticals Segment Value (US$ Mn), By Region 2013 to 2018
TABLE. 33 Global Pharmaceuticals Segment Volume (Tons), By Region 2013 to 2018
TABLE. 34 Global Pharmaceuticals Segment Value (US$ Mn), By Region 2019 to 2027
TABLE. 35 Global Pharmaceuticals Segment Volume (Tons), By Region 2019 to 2027
TABLE. 36 Global Pharmaceuticals Segment Market Share, By Region 2013 to 2018
TABLE. 37 Global Pharmaceuticals Segment Market Share, By Region 2019 to 2027
TABLE. 38 Global Pharmaceuticals Segment Y-o-Y, By Region 2019 to 2027
TABLE. 39 Global Animal Nutrition Segment Value (US$ Mn), By Region 2013 to 2018
TABLE. 40 Global Animal Nutrition Segment Volume (Tons), By Region 2013 to 2018
TABLE. 41 Global Animal Nutrition Segment Value (US$ Mn), By Region 2019 to 2027
TABLE. 42 Global Animal Nutrition Segment Volume (Tons), By Region 2019 to 2027
TABLE. 43 Global Animal Nutrition Segment Market Share, By Region 2013 to 2018
TABLE. 44 Global Animal Nutrition Segment Market Share, By Region 2019 to 2027
TABLE. 45 Global Animal Nutrition Segment Y-o-Y, By Region 2019 to 2027
TABLE. 46 Global Cosmeceuticals Segment Value (US$ Mn), By Region 2013 to 2018
TABLE. 47 Global Cosmeceuticals Segment Volume (Tons), By Region 2013 to 2018
TABLE. 48 Global Cosmeceuticals Segment Value (US$ Mn), By Region 2019 to 2027
TABLE. 49 Global Cosmeceuticals Segment Volume (Tons), By Region 2019 to 2027
TABLE. 50 Global Cosmeceuticals Segment Market Share, By Region 2013 to 2018
TABLE. 51 Global Cosmeceuticals Segment Market Share, By Region 2019 to 2027
TABLE. 52 Global Cosmeceuticals Segment Y-o-Y, By Region 2019 to 2027
TABLE. 53 Global Others Segment Value (US$ Mn), By Region 2013 to 2018
TABLE. 54 Global Others Segment Volume (Tons), By Region 2013 to 2018
TABLE. 55 Global Others Segment Value (US$ Mn), By Region 2019 to 2027
TABLE. 56 Global Others Segment Volume (Tons), By Region 2019 to 2027
TABLE. 57 Global Others Segment Market Share, By Region 2013 to 2018
TABLE. 58 Global Others Segment Market Share, By Region 2019 to 2027
TABLE. 59 Global Others Segment Y-o-Y, By Region 2019 to 2027
TABLE. 60 North America Current Expenditure on Health, (% of GDP), by Country, 2010 to 2016
TABLE. 61 North America Per Capita Health Expenditure (US$ PPP), by Country, 2010 to 2016
TABLE. 62 North America Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010 to 2016
TABLE. 63 North America Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010 to 2016
TABLE. 64 North America Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010 to 2016
TABLE. 65 North America Market Value (US$ Mn), By Country 2013 to 2018
TABLE. 66 North America Market Volume (Tons), By Country 2013 to 2018
TABLE. 67 North America Market Value (US$ Mn), By Country 2019 to 2027
TABLE. 68 North America Market Volume (Tons), By Country 2019 to 2027
TABLE. 69 North America Market Value (US$ Mn), By Form 2013 to 2018
TABLE. 70 North America Market Value (US$ Mn), By Form 2019 to 2027
TABLE. 71 North America Market Value (US$ Mn), By End Use 2013 to 2018
TABLE. 72 North America Market Value (US$ Mn), By End Use 2019 to 2027
TABLE. 73 Latin America Current Expenditure on Health, (% of GDP), by Country, 2010 to 2016
TABLE. 74 Latin America Per Capita Health Expenditure (US$ PPP), by Country, 2010 to 2016
TABLE. 75 Latin America Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010 to 2016
TABLE. 76 Latin America Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010 to 2016
TABLE. 77 Latin America Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010 to 2016
TABLE. 78 Latin America Market Value (US$ Mn), By Country 2013 to 2018
TABLE. 79 Latin America Market Volume (Tons), By Country 2013 to 2018
TABLE. 80 Latin America Market Value (US$ Mn), By Country 2019 to 2027
TABLE. 81 Latin America Market Volume (Tons), By Country 2019 to 2027
TABLE. 82 Latin America Market Value (US$ Mn), By Form 2013 to 2018
TABLE. 83 Latin America Market Value (US$ Mn), By Form 2019 to 2027
TABLE. 84 Latin America Market Value (US$ Mn), By End Use 2013 to 2018
TABLE. 85 Latin America Market Value (US$ Mn), By End Use 2019 to 2027
TABLE. 86 Europe Current Expenditure on Health, (% of GDP), by Country, 2010 to 2016
TABLE. 87 Europe Per Capita Health Expenditure (US$ PPP), by Country, 2010 to 2016
TABLE. 88 Europe Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010 to 2016
TABLE. 89 Europe Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010 to 2016
TABLE. 90 Europe Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010 to 2016
TABLE. 91 Europe Market Value (US$ Mn), By Country 2013 to 2018
TABLE. 92 Europe Market Volume (Tons), By Country 2013 to 2018
TABLE. 93 Europe Market Value (US$ Mn), By Country 2019 to 2027
TABLE. 94 Europe Market Volume (Tons), By Country 2019 to 2027
TABLE. 95 Europe Market Value (US$ Mn), By Form 2013 to 2018
TABLE. 96 Europe Market Value (US$ Mn), By Form 2019 to 2027
TABLE. 97 Europe Market Value (US$ Mn), By End Use 2013 to 2018
TABLE. 98 Europe Market Value (US$ Mn), By End Use 2019 to 2027
TABLE. 99 Japan Current Expenditure on Health, (% of GDP), by Country, 2010 to 2016
TABLE. 100 Japan Per Capita Health Expenditure (US$ PPP), by Country, 2010 to 2016
TABLE. 101 Japan Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010 to 2016
TABLE. 102 Japan Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010 to 2016
TABLE. 103 Japan Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010 to 2016
TABLE. 104 Japan Market Value (US$ Mn), By Country 2013 to 2018
TABLE. 105 Japan Market Volume (Tons), By Country 2013 to 2018
TABLE. 106 Japan Market Value (US$ Mn), By Country 2019 to 2027
TABLE. 107 Japan Market Volume (Tons), By Country 2019 to 2027
TABLE. 108 Japan Market Value (US$ Mn), By Form 2013 to 2018
TABLE. 109 Japan Market Value (US$ Mn), By Form 2019 to 2027
TABLE. 110 Japan Market Value (US$ Mn), By End Use 2013 to 2018
TABLE. 111 Japan Market Value (US$ Mn), By End Use 2019 to 2027
TABLE. 112 APEJ Current Expenditure on Health, (% of GDP), by Country, 2010 to 2016
TABLE. 113 APEJ Per Capita Health Expenditure (US$ PPP), by Country, 2010 to 2016
TABLE. 114 APEJ Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010 to 2016
TABLE. 115 APEJ Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010 to 2016
TABLE. 116 APEJ Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010 to 2016
TABLE. 117 APEJ Market Value (US$ Mn), By Country 2013 to 2018
TABLE. 118 APEJ Market Volume (Tons), By Country 2013 to 2018
TABLE. 119 APEJ Market Value (US$ Mn), By Country 2019 to 2027
TABLE. 120 APEJ Market Volume (Tons), By Country 2019 to 2027
TABLE. 121 APEJ Market Value (US$ Mn), By Form 2013 to 2018
TABLE. 122 APEJ Market Value (US$ Mn), By Form 2019 to 2027
TABLE. 123 APEJ Market Value (US$ Mn), By End Use 2013 to 2018
TABLE. 124 APEJ Market Value (US$ Mn), By End Use 2019 to 2027
TABLE. 125 MEA Current Expenditure on Health, (% of GDP), by Country, 2010 to 2016
TABLE. 126 MEA Per Capita Health Expenditure (US$ PPP), by Country, 2010 to 2016
TABLE. 127 MEA Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010 to 2016
TABLE. 128 MEA Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010 to 2016
TABLE. 129 MEA Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010 to 2016
TABLE. 130 MEA Market Value (US$ Mn), By Country 2013 to 2018
TABLE. 131 MEA Market Volume (Tons), By Country 2013 to 2018
TABLE. 132 MEA Market Value (US$ Mn), By Country 2019 to 2027
TABLE. 133 MEA Market Volume (Tons), By Country 2019 to 2027
TABLE. 134 MEA Market Value (US$ Mn), By Form 2013 to 2018
TABLE. 135 MEA Market Value (US$ Mn), By Form 2019 to 2027
TABLE. 136 MEA Market Value (US$ Mn), By End Use 2013 to 2018
TABLE. 137 MEA Market Value (US$ Mn), By End Use 2019 to 2027
FIG. 1 Global Market Value (US$ Mn), 2013 to 2018
FIG. 2 Global Market Value (US$ Mn) Forecast, 2019 to 2027
FIG. 3 Global Market Value (US$ Mn) and Y-o-Y, 2019 to 2027
FIG. 4 Global Powder Segment Market Value (US$ Mn) By Region, 2013 to 2018
FIG. 5 Global Powder Segment Market Value (US$ Mn) By Region, 2019 to 2027
FIG. 6 Global Powder Segment Y-o-Y Growth Rate, By Region, 2019 to 2027
FIG. 7 Global Granular Segment Market Value (US$ Mn) By Region, 2013 to 2018
FIG. 8 Global Granular Segment Market Value (US$ Mn) By Region, 2019 to 2027
FIG. 9 Global Granular Segment Y-o-Y Growth Rate, By Region, 2019 to 2027
FIG. 10 Global Liquid Segment Market Value (US$ Mn) By Region, 2013 to 2018
FIG. 11 Global Liquid Segment Market Value (US$ Mn) By Region, 2019 to 2027
FIG. 12 Global Liquid Segment Y-o-Y Growth Rate, By Region, 2019 to 2027
FIG. 13 Global Human Nutrition Segment Market Value (US$ Mn) By Region, 2013 to 2018
FIG. 14 Global Human Nutrition Segment Market Value (US$ Mn) By Region, 2019 to 2027
FIG. 15 Global Human Nutrition Segment Y-o-Y Growth Rate, By Region, 2019 to 2027
FIG. 16 Global Pharmaceuticals Segment Market Value (US$ Mn) By Region, 2013 to 2018
FIG. 17 Global Pharmaceuticals Segment Market Value (US$ Mn) By Region, 2019 to 2027
FIG. 18 Global Pharmaceuticals Segment Y-o-Y Growth Rate, By Region, 2019 to 2027
FIG. 19 Global Animal Nutrition Segment Market Value (US$ Mn) By Region, 2013 to 2018
FIG. 20 Global Animal Nutrition Segment Market Value (US$ Mn) By Region, 2019 to 2027
FIG. 21 Global Animal Nutrition Segment Y-o-Y Growth Rate, By Region, 2019 to 2027
FIG. 22 Global Cosmeceuticals Segment Market Value (US$ Mn) By Region, 2013 to 2018
FIG. 23 Global Cosmeceuticals Segment Market Value (US$ Mn) By Region, 2019 to 2027
FIG. 24 Global Cosmeceuticals Segment Y-o-Y Growth Rate, By Region, 2019 to 2027
FIG. 25 Global Others Segment Market Value (US$ Mn) By Region, 2013 to 2018
FIG. 26 Global Others Segment Market Value (US$ Mn) By Region, 2019 to 2027
FIG. 27 Global Others Segment Y-o-Y Growth Rate, By Region, 2019 to 2027
FIG. 28 North America Market Value (US$ Mn), By Country 2013 to 2018
FIG. 29 North America Market Value (US$ Mn), By Country 2019 to 2027
FIG. 30 North America Market Value (US$ Mn), By Form 2013 to 2018
FIG. 31 North America Market Value (US$ Mn), By Form 2019 to 2027
FIG. 32 North America Market Value (US$ Mn), By End Use 2013 to 2018
FIG. 33 North America Market Value (US$ Mn), By End Use 2019 to 2027
FIG. 34 Latin America Market Value (US$ Mn), By Country 2013 to 2018
FIG. 35 Latin America Market Value (US$ Mn), By Country 2019 to 2027
FIG. 36 Latin America Market Value (US$ Mn), By Form 2013 to 2018
FIG. 37 Latin America Market Value (US$ Mn), By Form 2019 to 2027
FIG. 38 Latin America Market Value (US$ Mn), By End Use 2013 to 2018
FIG. 39 Latin America Market Value (US$ Mn), By End Use 2019 to 2027
FIG. 40 Europe Market Value (US$ Mn), By Country 2013 to 2018
FIG. 41 Europe Market Value (US$ Mn), By Country 2019 to 2027
FIG. 42 Europe Market Value (US$ Mn), By Form 2013 to 2018
FIG. 43 Europe Market Value (US$ Mn), By Form 2019 to 2027
FIG. 44 Europe Market Value (US$ Mn), By End Use 2013 to 2018
FIG. 45 Europe Market Value (US$ Mn), By End Use 2019 to 2027
FIG. 46 Japan Market Value (US$ Mn), By Country 2013 to 2018
FIG. 47 Japan Market Value (US$ Mn), By Country 2019 to 2027
FIG. 48 Japan Market Value (US$ Mn), By Form 2013 to 2018
FIG. 49 Japan Market Value (US$ Mn), By Form 2019 to 2027
FIG. 50 Japan Market Value (US$ Mn), By 2013 to 2018
FIG. 51 Japan Market Value (US$ Mn), By End Use 2019 to 2027
FIG. 52 APEJ Market Value (US$ Mn), By Country 2013 to 2018
FIG. 53 APEJ Market Value (US$ Mn), By Country 2019 to 2027
FIG. 54 APEJ Market Value (US$ Mn), By Form 2013 to 2018
FIG. 55 APEJ Market Value (US$ Mn), By Form 2019 to 2027
FIG. 56 APEJ Market Value (US$ Mn), By End Use 2013 to 2018
FIG. 57 APEJ Market Value (US$ Mn), By End Use 2019 to 2027
FIG. 58 MEA Market Value (US$ Mn), By Country 2013 to 2018
FIG. 59 MEA Market Value (US$ Mn), By Country 2019 to 2027
FIG. 60 MEA Market Value (US$ Mn), By Form 2013 to 2018
FIG. 61 MEA Market Value (US$ Mn), By Form 2019 to 2027
FIG. 62 MEA Market Value (US$ Mn), By End Use 2013 to 2018
FIG. 63 MEA Market Value (US$ Mn), By End Use 2019 to 2027
Niacin and Niacinamide Market